Reportlinker Adds Stroke: Competing Treatments and Market Entry Considerations
NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Stroke: Competing Treatments and Market Entry Considerations
This report presents the findings of a global clinical survey on competing treatments for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 clinics worldwide, which provided detailed information of their treatment practices. This survey was carried out to evaluate competing therapies and market entry factors, relating to the treatment of Stroke.
In 2008, the World Stroke Congress reported that 20 million Stroke events occur globally each year and account for 5.7 million deaths. Stroke is now the second most common cause of death worldwide and a major cause of disability. The incidence of Stroke is expected to increase by 30% over the next decade (6th World Stroke Congress, Vienna, Austria, 24th-27th September 2008).
In a field where therapies are often unsatisfactory, physicians seek to extend their understanding and use of available treatments to improve patient outcomes. Knowledge in these areas is also important to drug developers, who seek a better understanding of prescribing practices and treatment needs and limitations from the clinician's perspective, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted a global survey on current treatments and drug prescribing practices for Stroke. This survey involved the participation of more than 230 clinical centres in 41 countries.
Overview:
* Global quantitative data on treatments and drug prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), provided by more than 230 clinics in 41 countries.
* More than 98% of study participants are practicing physicians, working in areas of Stroke treatment. Of these, 65% are specialists in Stroke treatment. Leading participant countries were USA, Italy, India, Canada, Japan, Germany, Spain, Belgium and China.
* More than 60% of the clinical centres participating in this study were hospital specialist Stroke units, specialist Stroke practices or private Stroke clinics.
* Detailed information on drugs classes used in the treatment of patients with Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), together with population-based drug prescribing profiles.
* Quantitative prescribing data on specific antiplatelet, anticoagulant, thrombolytic and other drugs used in the treatment of Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA).
* The percentage of Ischaemic Stroke patients prescribed the antiplatelets aspirin (e.g. Aspro®), dipyridamole (e.g. Persantine®), clopidogrel (e.g. Plavix®), aspirin/dipyridamol (e.g. Asasantin®), ticlopidine (e.g. Ticlid®) and others (specified).
* The percentage of Ischaemic Stroke patients prescribed the coagulants warfarin (e.g. Coumadin®), heparin (e.g. Hepalean®), dicoumarol (e.g. Dicoumarol), antithrombin III (e.g. Thrombate III®), argatroban (e.g. Novastan®), bivalirudin (e.g. Angiomax®), sandoparin (e.g. Certoparin®), enoxaparin (e.g. Lovenox®), ethyl biscoumacetate (e.g. Tromexan®), nadroparin (e.g. Fraxiparine®) or others (specified)
* The percentage of Ischaemic Stroke patients prescribed the thrombolytic drug Tissue Plasminogen Activator (e.g. Alteplase®) or others (specified).
* The percentage of Haemorrhagic Stroke patients prescribed clotting factor (e.g. vitamin K), clotting proteins (e.g. prothrombin), calcium channel blockers (e.g. nimodipine), antihypertensives, platelets, plasma or other (specified).
* Prescribing practices on the use of specific drug combinations, used in the treatment of Ischaemic and Haemorrhagic Stroke.
* The percentage of Haemorrhagic Stroke patients treated surgically by aneurysm clipping, endovascular treatment of aneurysms, surgical arteriovenous malformation (AVM) removal, steriotactic radiosurgery, endovascular treatment of AVMs, removal of haematoma, ventriculostomy, carotid endarterectomy, craniotomy and others (specified).
* From the clinician's perspective: current limitations in the diagnosis and treatment of Stroke.
Report Contents
1. Introduction
2. Stroke therapy survey
3. Survey participants
4. Stroke diagnosis
5. Limitations of stroke diagnostics
6. Drug Classes used to treat transient Ischaemic attack (TIA)
7. Drug classes used to treat Ischaemic Stroke
8. Antiplatelet drugs used to treat Ischaemic Stroke
9. Anticoagulant drugs used to treat Ischaemic Stroke
10. Thrombolytic drugs used to treat Ischaemic Stroke
11. Combined drugs used to treat Ischaemic Stroke
12. The use of drug therapy and/or surgery to treat Haemorrhagic Stroke
13. Drugs used to treat Haemorrhagic Stroke
14. The use of combined drugs to treat Haemorrhagic Stroke
15. Surgical methods to treat Haemorrhagic Stroke
16. Study participants
Appendix 1
Figures
Figure 3.1 Participant Countries
Figure 3.2 Participant Organisations
Figure 3.3 Participating Physicians
Figure 4.1 Percentage of patients diagnosed with Transient Ischaemic Attack (TIA)
Figure 4.2 Percentage of patients diagnosed with Ischaemic Stroke
Figure 4.3 Percentage of patients diagnosed with Haemorrhagic Stroke
Figure 4.4 Percentage patients with other conditions
Figure 4.5 Average percentage of patients with Transient Ischaemic Attack (TIA), Ischaemic Stroke, Haemorrhagic Stroke or other conditions
Figure 4.6 Average percentage of patients tested for Stroke, and diagnosed with other conditions
Figure 5.1 Limitations in the diagnosis of Stroke, reported by study participants
Figure 6.1 Percentage of patients receiving antiplatelet drugs in Transient Ischaemic Attack (TIA)
Figure 6.2 Percentage of patients receiving anticoagulant drugs in Transient Ischaemic Attack (TIA)
Figure 6.3 Percentage of patients receiving thrombolytic drugs in Transient Ischaemic Attack (TIA)
Figure 6.4 Percentage of patients receiving other drugs in Transient Ischaemic Attack (TIA)
Figure 6.5 Average percentage of Transient Ischaemic Attack (TIA) patients receiving antiplatelet, anticoagulant, thrombolytic or other drugs
Figure 7.1 Percentage of patients receiving antiplatelet drugs in Ischaemic Stroke
Figure 7.2 Percentage of patients receiving anticoagulant drugs in Ischaemic Stroke
Figure 7.3 Percentage of patients receiving thrombolytics drugs in Ischaemic Stroke
Figure 7.4 Percentage of patients receiving other drugs in Ischaemic Stroke
Figure 7.5 Average percentage of Ischaemic Stroke patients prescribed antiplatelet, anticoagulant, thrombolytic or other drugs
Figure 8.1 Percentage of patients receiving aspirin in Ischaemic Stroke
Figure 8.2 Percentage of patients receiving dipyridamole in Ischaemic Stroke
Figure 8.3 Percentage of patients receiving clopidogrel in Ischaemic Stroke
Figure 8.4 Percentage of patients receiving dipyridamol/aspirin in Ischaemic Stroke
Figure 8.5 Percentage of patients receiving ticlopidine in Ischaemic Stroke
Figure 8.6 Percentage of patients receiving other drugs in Ischaemic Stroke
Figure 8.7 Average percentage of patients prescribed specific antiplatelet drugs for the treatment of Ischaemic Stroke
Figure 8.8 Other antiplatelet drugs prescribed to patients with Ischaemic Stroke
Figure 9.1 Percentage of patients receiving the anticoagulant warfarin in the treatment of Ischaemic Stroke
Figure 9.2 Percentage of patients receiving the anticoagulant heparin in the treatment of Ischaemic Stroke
Figure 9.3 Percentage of patients receiving the anticoagulant dicoumarol in the treatment of Ischaemic Stroke
Figure 9.4 Percentage of patients receiving the anticoagulant antithrombin III in the treatment of Ischaemic Stroke
Figure 9.5 Percentage of patients receiving the anticoagulant argatroban in the treatment of Ischaemic Stroke
Figure 9.6 Percentage of patients receiving the anticoagulant bivalirudin in the treatment of Ischaemic Stroke
Figure 9.7 Percentage of patients receiving the anticoagulant sandoparin in the treatment of Ischaemic Stroke
Figure 9.8 Percentage of patients receiving the anticoagulant enoxaparin in the treatment of Ischaemic Stroke
Figure 9.9 Percentage of patients receiving the anticoagulant ethyl biscoumacetate in the treatment of Ischaemic Stroke
Figure 9.10 Percentage of patients receiving the anticoagulant nadroparin in the treatment of Ischaemic Stroke
Figure 9.11 Percentage of patients receiving other anticoagulant drugs in the treatment of Ischaemic Stroke
Figure 9.12 Average percentage of patients prescribed specific anticoagulant drugs for the treatment of Ischaemic Stroke
Figure 10.1 Percentage of Ischaemic Stroke patients prescribed tissue plasminogen activator for Ischaemic Stroke
Figure 11.1 Use of combined drugs to treat ischemic Stroke
Figure 11.2 Combined drug classes used in the treatment of Ischaemic Stroke
Figure 12.1 Use of drugs alone in the treatment of Haemorrhagic Stroke
Figure 12.2 Combined use of drugs and surgery in the treatment of Haemorrhagic Stroke
Figure 12.3 Use of surgery alone in the treatment of Haemorrhagic Stroke
Figure 12.4 Average use of drugs alone, combined drugs and surgery, surgery alone and other treatments for Haemorrhagic Stroke
Figure 13.1 Percentage of Haemorrhagic Stroke patients prescribed a clotting factor (e.g. vitamin k)
Figure 13.2 Percentage of Haemorrhagic Stroke patients prescribed a clotting protein (e.g. prothrombin)
Figure 13.3 Percentage of Haemorrhagic Stroke patients prescribed a calcium channel blocker
Figure 13.4 Percentage of Haemorrhagic Stroke patients prescribed antihypertensives
Figure 13.5 Percentage of Haemorrhagic Stroke patients prescribed platelets
Figure 13.6 Percentage of Haemorrhagic Stroke patients treated with plasma
Figure 13.7 Percentage of Haemorrhagic Stroke patients prescribed other drugs
Figure 13.8 Average percentage of patients prescribed specific drugs for the treatment of Ischaemic Stroke
Figure 14.1 Use of combined drugs in the treatment of Haemorrhagic Stroke
Figure 14.2 Drug combinations used in the treatment of Haemorrhagic Stroke
Figure 15.1 Mean percentage frequency of use of the top ten surgical methods, for haemorrhagic Stroke.
Tables
Table 3.1 Participant Countries
Table 4.1 Average percentage of patients tested for Stroke, who were diagnosed with other
conditions
Table 11.1 Combined drug classes used in the treatment of Ischaemic Stroke
Table 14.1 Drug combinations used in the treatment of Haemorrhagic Stroke
Table 16.1 Study participants
Appendix
Appendix 1. Responses given by study participants to the question: What are the major issues and challenges associated with the treatment of Stroke? These responses (which in some cases may be brief, informal or abbreviated) are presented verbatim, except in those cases where minor grammatical or typographical corrections have been made for reasons of clarity.
To order this report:
: Stroke: Competing Treatments and Market Entry Considerations
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article